These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12113127)

  • 1. Berlex Laboratories to market new treatment for B-CLL.
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):3. PubMed ID: 12113127
    [No Abstract]   [Full Text] [Related]  

  • 2. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
    Demko S; Summers J; Keegan P; Pazdur R
    Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the use of alemtuzumab in CLL.
    Stilgenbauer S
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437
    [No Abstract]   [Full Text] [Related]  

  • 5. NCCN: New directions in chronic lymphocytic leukemia.
    O'Brien S
    Cancer Control; 2001; 8(6 Suppl 2):114-7. PubMed ID: 11760553
    [No Abstract]   [Full Text] [Related]  

  • 6. [A new therapeutic alternative in chronic B-lymphocytic leukemia].
    Portal E
    Rev Infirm; 2002 Dec; (86):38-40. PubMed ID: 12630232
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab.
    Laurenti L; Tarnani M; Innocenti I; Savino G; Battendieri R; Larocca LM; Chiusolo P; Sorà F; Sica S; Efremov D; Leone G
    J Clin Oncol; 2008 Nov; 26(32):5299-301. PubMed ID: 18854557
    [No Abstract]   [Full Text] [Related]  

  • 8. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
    Byrd JC; Rai KR
    Semin Oncol; 2000 Aug; 27(4):xii-xv; discussion xv-xvi. PubMed ID: 10950363
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
    Grey M
    Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
    [No Abstract]   [Full Text] [Related]  

  • 10. Monoclonal antibody licensed for third-line treatment of B-cell chronic lymphocytic leukemia.
    Thompson CA
    Am J Health Syst Pharm; 2001 Jul; 58(13):1174. PubMed ID: 11449871
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
    Lin TS; Moran M; Lucas M; Waymer S; Jefferson S; Fischer DB; Grever MR; Byrd JC
    Hematol Oncol Clin North Am; 2004 Aug; 18(4):895-913, ix-x. PubMed ID: 15325705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab (Millennium/ILEX).
    Dumont FJ
    Curr Opin Investig Drugs; 2001 Jan; 2(1):139-60. PubMed ID: 11527007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approval of obinutuzumab as a breakthrough therapy for chronic lymphocytic leukemia.
    Small S
    Clin Adv Hematol Oncol; 2013 Dec; 11(12):809-10. PubMed ID: 25016628
    [No Abstract]   [Full Text] [Related]  

  • 14. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.
    Karlsson C; Norin S; Kimby E; Sander B; Porwit Macdonald A; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
    Leukemia; 2006 Dec; 20(12):2204-7. PubMed ID: 17051245
    [No Abstract]   [Full Text] [Related]  

  • 15. Alemtuzumab in chronic lymphocytic leukemia.
    James DF; Kipps TJ
    Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.
    Stilgenbauer S; Döhner H
    N Engl J Med; 2002 Aug; 347(6):452-3. PubMed ID: 12167696
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment.
    Rai KR
    Haematologica; 1999 Jun; 84 Suppl EHA-4():94-5. PubMed ID: 10907481
    [No Abstract]   [Full Text] [Related]  

  • 19. Obinutuzumab breaks through to FDA approval.
    Cancer Discov; 2014 Jan; 4(1):OF6. PubMed ID: 24402958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.